Eupraxia Pharmaceuticals (NASDAQ:EPRX) Earns Buy Rating from Analysts at Rodman & Renshaw

Rodman & Renshaw assumed coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a research report released on Thursday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $9.00 price objective on the stock.

Eupraxia Pharmaceuticals Stock Performance

Shares of NASDAQ EPRX opened at $3.13 on Thursday. The company’s fifty day moving average price is $2.67 and its 200 day moving average price is $2.68. Eupraxia Pharmaceuticals has a 1 year low of $2.20 and a 1 year high of $5.58. The company has a market capitalization of $85.41 million and a PE ratio of -4.35.

Institutional Trading of Eupraxia Pharmaceuticals

A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC bought a new stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 13,000 shares of the company’s stock, valued at approximately $34,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.